ASAM Pocket Guidelines and Patient Guide

ASAM Opioid Patient Guide 2020

ASAM Opioid Addiction Treatment GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1275542

Contents of this Issue

Navigation

Page 16 of 19

17 • The clinician may also recommend methadone or buprenorphine for pregnant women who are in recovery from opioid use disorder if the patient is at risk for relapse during pregnancy. • Methadone or buprenorphine are the best options to treat opioid use disorder during pregnancy. However, if the patient is taking naltrexone prior to pregnancy and wants to continue it, the patient should discuss the potential risks with a clinician. Not enough is known about the safety of naltrexone during pregnancy. • While methadone and buprenorphine have some similarities to other opioids like heroin or oxycodone, their specific properties make them much safer during pregnancy when used under the care of a clinician. These medications are longer acting, preventing opioid withdrawal, opioid overdoses, and the highs and lows that can harm the development of the fetus. • Later in pregnancy the clinician may increase the dose of medication or have the patient take the medication more frequently to prevent cravings and support a more stable environment for the fetus. • The clinician may recommend counseling or other behavioral treatments in addition to medication. • Patients who are taking methadone or buprenorphine as prescribed, and are without other contraindications for breastfeeding, can and should breastfeed. • After delivery the clinician will evaluate the patient to see if there is a need to adjust the dose of methadone or buprenorphine. Since there is a risk for relapse and overdose in the first year after delivery, patients should not stop taking these medications during this time.

Articles in this issue

view archives of ASAM Pocket Guidelines and Patient Guide - ASAM Opioid Patient Guide 2020